{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-009737","form_type":"8-K","ticker":"SCNX","cik":"0001382574","company_name":"Scienture Holdings, Inc.","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.485078+00:00","generated_at":"2026-05-25T00:59:30.776880+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Scienture gets exclusive US rights to commercialize REZENOPY naloxone nasal spray from Kindeva","bullets":["Exclusive 10-year US license to commercialize REZENOPY (naloxone HCl 10mg) from Kindeva; term expires 10 yrs from first commercial sale.","Supply price $9.20/unit; profit-sharing 10% of net sales (8% upon generic entry); additional 5% until $12.8M NDA cost recovered.","Milestone payments up to $10M based on net sales targets; $1M upfront milestones due in stages.","Minimum order: 3 batches of 450,000 units/year from 2027 or $1.242M/year; $189M total naloxone market (IQVIA MAT Dec 2024)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-009737","json":"https://secwatch.observer/filing/0001493152-25-009737.json","markdown":"https://secwatch.observer/filing/0001493152-25-009737.md","text":"https://secwatch.observer/filing/0001493152-25-009737.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382574/000149315225009737/0001493152-25-009737-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382574/000149315225009737/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T00:59:30.776880+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}